Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer.

Torquato S, Pallavajjala A, Goldstein A, Toro PV, Silberstein JL, Lee J, Nakazawa M, Waters I, Chu D, Shinn D, Groginski T, Hughes RM, Simons BW, Khan H, Feng Z, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Eisenberger MA, Antonarakis ES, Trock BJ, Park BH, Hurley PJ.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00227. Epub 2019 Apr 3.

2.

The dual-staged pathway for closure in cloacal exstrophy: Successful evolution in collaborative surgical practice.

Jayman J, Michaud J, Maruf M, Trock BJ, Kasprenski M, Sponseller P, Gearhart J.

J Pediatr Surg. 2019 Apr 8. pii: S0022-3468(19)30014-4. doi: 10.1016/j.jpedsurg.2019.01.005. [Epub ahead of print]

PMID:
31003729
3.

Meta-analysis of randomized controlled trials that assess the efficacy of low-intensity shockwave therapy for the treatment of erectile dysfunction.

Campbell JD, Trock BJ, Oppenheim AR, Anusionwu I, Gor RA, Burnett AL.

Ther Adv Urol. 2019 Mar 29;11:1756287219838364. doi: 10.1177/1756287219838364. eCollection 2019 Jan-Dec.

4.

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M.

Cancer Cell. 2019 Mar 18;35(3):401-413.e6. doi: 10.1016/j.ccell.2019.01.008. Epub 2019 Feb 14.

PMID:
30773341
5.

ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS.

Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R.

Ann Appl Stat. 2018 Sep;12(3):1773-1795. doi: 10.1214/17-AOAS1130. Epub 2018 Sep 11.

6.

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.

Kim HL, Li P, Huang HC, Deheshi S, Marti T, Knudsen B, Abou-Ouf H, Alam R, Lotan TL, Lam LLC, du Plessis M, Davicioni E, Fleshner N, Lane BR, Ross AE, Davis JW, Mohler JL, Trock BJ, Klein EA, Tosoian JJ, Hyndman ME, Bismar TA.

Prostate Cancer Prostatic Dis. 2018 Dec 12. doi: 10.1038/s41391-018-0101-6. [Epub ahead of print]

PMID:
30542054
7.

Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.

Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):584-590. doi: 10.1158/1055-9965.EPI-18-0667. Epub 2018 Nov 12.

PMID:
30420441
8.

Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.

Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K.

Prostate Cancer Prostatic Dis. 2019 May;22(2):292-302. doi: 10.1038/s41391-018-0103-4. Epub 2018 Oct 26.

PMID:
30367117
9.

Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer.

Guedes LB, Morais CL, Fedor H, Hicks J, Gurel B, Melamed J, Lee P, Gopalan A, Knudsen BS, True LD, Scher HI, Fine SW, Trock BJ, De Marzo AM, Lotan TL.

Arch Pathol Lab Med. 2019 Mar;143(3):338-348. doi: 10.5858/arpa.2018-0068-OA. Epub 2018 Oct 8.

PMID:
30295067
10.

PTEN status assessment in the Johns Hopkins active surveillance cohort.

Tosoian JJ, Guedes LB, Morais CL, Mamawala M, Ross AE, De Marzo AM, Trock BJ, Han M, Carter HB, Lotan TL.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):176-181. doi: 10.1038/s41391-018-0093-2. Epub 2018 Oct 2.

11.

Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.

Druskin SC, Mamawala M, Tosoian JJ, Epstein JI, Pavlovich CP, Carter HB, Trock BJ.

J Urol. 2019 Jan;201(1):98-104. doi: 10.1016/j.juro.2018.08.023.

PMID:
30114397
12.

Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.

Bismar TA, Hegazy S, Feng Z, Yu D, Donnelly B, Palanisamy N, Trock BJ.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2117-2125. doi: 10.1007/s00432-018-2730-5. Epub 2018 Aug 12.

PMID:
30101374
13.

Predictors of a successful primary bladder closure in cloacal exstrophy: A multivariable analysis.

Jayman J, Tourchi A, Feng Z, Trock BJ, Maruf M, Benz K, Kasprenski M, Baumgartner T, Friedlander D, Sponseller P, Gearhart J.

J Pediatr Surg. 2019 Mar;54(3):491-494. doi: 10.1016/j.jpedsurg.2018.06.030. Epub 2018 Jul 6.

PMID:
30029844
14.

Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study.

Alam R, Patel HD, Osumah T, Srivastava A, Gorin MA, Johnson MH, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM.

BJU Int. 2019 Jan;123(1):42-50. doi: 10.1111/bju.14490. Epub 2018 Aug 9.

PMID:
30019484
15.

Predictors and outcomes of perioperative blood transfusions in classic bladder exstrophy repair: A single institution study.

Maruf M, Jayman J, Kasprenski M, Benz K, Feng Z, Friedlander D, Baumgartner T, Trock BJ, Di Carlo H, Sponseller PD, Gearhart JP.

J Pediatr Urol. 2018 Oct;14(5):430.e1-430.e6. doi: 10.1016/j.jpurol.2018.04.025. Epub 2018 Jun 7.

PMID:
29914824
16.

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.

Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R.

Ann Intern Med. 2018 Jan 2;168(1):1-9. doi: 10.7326/M17-0548. Epub 2017 Nov 28.

17.

Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides.

Baena-Del Valle JA, Zheng Q, Hicks JL, Fedor H, Trock BJ, Morrissey C, Corey E, Cornish TC, Sfanos KS, De Marzo AM.

Am J Clin Pathol. 2017 Nov 2;148(5):398-415. doi: 10.1093/ajcp/aqx094.

18.

Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry.

Uzosike AC, Patel HD, Alam R, Schwen ZR, Gupta M, Gorin MA, Johnson MH, Gausepohl H, Riffon MF, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME, Pierorazio PM.

J Urol. 2018 Mar;199(3):641-648. doi: 10.1016/j.juro.2017.09.087. Epub 2017 Sep 23.

PMID:
28951284
19.

Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?

Ludwig WW, Feng Z, Trock BJ, Humphreys E, Walsh PC.

J Urol. 2018 Jan;199(1):114-119. doi: 10.1016/j.juro.2017.08.041. Epub 2017 Aug 14.

PMID:
28818527
20.

Editorial Comment.

Trock BJ.

Urology. 2017 Sep;107:73-74. doi: 10.1016/j.urology.2017.02.058. Epub 2017 Jul 13. No abstract available.

PMID:
28712713
22.

A Framework for Treatment Decision Making at Prostate Cancer Recurrence.

Lange JM, Trock BJ, Gulati R, Etzioni R.

Med Decis Making. 2017 Nov;37(8):905-913. doi: 10.1177/0272989X17711913. Epub 2017 May 31.

23.

Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.

Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, Spratt DE, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, Kolisnik T, Margrave J, Yousefi K, Choeurng V, Davicioni E, Trock BJ, Kane CJ, Pollack A, Davis JW, Feng FY, Klein EA.

Eur Urol. 2017 Nov;72(5):845-852. doi: 10.1016/j.eururo.2017.05.009. Epub 2017 May 19.

24.

Prostate MRI prior to radical prostatectomy: effects on nerve sparing and pathological margin status.

Druskin SC, Liu JJ, Young A, Feng Z, Dianat SS, Ludwig WW, Trock BJ, Macura KJ, Pavlovich CP.

Res Rep Urol. 2017 Apr 18;9:55-63. doi: 10.2147/RRU.S128499. eCollection 2017.

25.

Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.

Karnes RJ, Choeurng V, Ross AE, Schaeffer EM, Klein EA, Freedland SJ, Erho N, Yousefi K, Takhar M, Davicioni E, Cooperberg MR, Trock BJ.

Eur Urol. 2018 Feb;73(2):168-175. doi: 10.1016/j.eururo.2017.03.036. Epub 2017 Apr 8.

26.

Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.

Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LLC, du Plessis M, Choeurng V, Haddad Z, Buerki C, Davicioni E, Weinmann S, Freedland SJ, Klein EA, Karnes RJ, Feng FY.

J Clin Oncol. 2017 Jun 20;35(18):1991-1998. doi: 10.1200/JCO.2016.70.2811. Epub 2017 Mar 30. Review.

27.

Patterns of Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy for Low-risk Men.

Chalfin HJ, Feng Z, Trock BJ, Partin AW.

Urology. 2017 Jun;104:143-149. doi: 10.1016/j.urology.2017.01.037. Epub 2017 Feb 21.

PMID:
28232176
28.

Detection fidelity of AR mutations in plasma derived cell-free DNA.

Goldstein A, Toro PV, Lee J, Silberstein JL, Nakazawa M, Waters I, Cravero K, Chu D, Cochran RL, Kim M, Shinn D, Torquato S, Hughes RM, Pallavajjala A, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Trock BJ, Eisenberger MA, Antonarakis ES, Park BH, Hurley PJ.

Oncotarget. 2017 Feb 28;8(9):15651-15662. doi: 10.18632/oncotarget.14926.

29.

CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS.

Partin AW, VAN Criekinge W, Trock BJ, Epstein JI, VAN Neste L.

Trans Am Clin Climatol Assoc. 2016;127:313-327.

30.

New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.

Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C, Humphreys E, Partin AW, Han M.

Eur Urol. 2017 Jun;71(6):907-912. doi: 10.1016/j.eururo.2016.11.006. Epub 2016 Nov 19.

PMID:
27876305
31.

The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.

Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C, Humphreys E, Partin AW, Han M.

J Urol. 2017 Apr;197(4):1060-1067. doi: 10.1016/j.juro.2016.11.079. Epub 2016 Nov 12.

PMID:
27847296
32.

SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort.

Johnson MH, Ross AE, Alshalalfa M, Erho N, Yousefi K, Glavaris S, Fedor H, Han M, Faraj SF, Bezerra SM, Netto G, Partin AW, Trock BJ, Davicioni E, Schaeffer EM.

J Urol. 2016 Nov;196(5):1436-1444. doi: 10.1016/j.juro.2016.05.092. Epub 2016 May 27.

PMID:
27238617
33.

A Prospective, Comparative Study of Quality of Life among Patients with Small Renal Masses Choosing Active Surveillance and Primary Intervention.

Patel HD, Riffon MF, Joice GA, Johnson MH, Chang P, Wagner AA, McKiernan JM, Trock BJ, Allaf ME, Pierorazio PM.

J Urol. 2016 Nov;196(5):1356-1362. doi: 10.1016/j.juro.2016.04.073. Epub 2016 Apr 30.

PMID:
27140071
34.

Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes.

Guerrero-Preston R, Valle BL, Jedlicka A, Turaga N, Folawiyo O, Pirini F, Lawson F, Vergura A, Noordhuis M, Dziedzic A, Pérez G, Renehan M, Guerrero-Diaz C, De Jesus Rodríguez E, Diaz-Montes T, Rodríguez Orengo J, Méndez K, Romaguera J, Trock BJ, Florea L, Sidransky D.

Cancer Prev Res (Phila). 2016 Dec;9(12):915-924. Epub 2016 Sep 26.

35.

Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential.

Klein EA, Santiago-Jiménez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, Freedland SJ, Ross AE.

J Urol. 2017 Jan;197(1):122-128. doi: 10.1016/j.juro.2016.08.091. Epub 2016 Aug 26.

PMID:
27569435
36.

Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting.

Mukherjee A, Kumar B, Hatano K, Russell LM, Trock BJ, Searson PC, Meeker AK, Pomper MG, Lupold SE.

Mol Cancer Ther. 2016 Oct;15(10):2541-2550. Epub 2016 Aug 2.

37.

Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.

Tosoian JJ, Almutairi F, Morais CL, Glavaris S, Hicks J, Sundi D, Humphreys E, Han M, De Marzo AM, Ross AE, Tomlins SA, Schaeffer EM, Trock BJ, Lotan TL.

Eur Urol. 2017 May;71(5):697-700. doi: 10.1016/j.eururo.2016.07.026. Epub 2016 Jul 28.

38.

Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance.

Mamawala MM, Rao K, Landis P, Epstein JI, Trock BJ, Tosoian JJ, Pienta KJ, Carter HB.

BJU Int. 2017 Jul;120(1):25-31. doi: 10.1111/bju.13608. Epub 2016 Aug 29.

39.

Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.

Tosoian JJ, Chappidi M, Feng Z, Humphreys EB, Han M, Pavlovich CP, Epstein JI, Partin AW, Trock BJ.

BJU Int. 2017 May;119(5):676-683. doi: 10.1111/bju.13573. Epub 2016 Jul 29.

41.

Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk.

Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Klein EA, Dicker AP, Freedland SJ, Karnes RJ, Schaeffer EM.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):277-82. doi: 10.1038/pcan.2016.15. Epub 2016 May 3.

42.

PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.

Trock BJ, Fedor H, Gurel B, Jenkins RB, Knudsen BS, Fine SW, Said JW, Carter HB, Lotan TL, De Marzo AM.

Mod Pathol. 2016 Jul;29(7):764-71. doi: 10.1038/modpathol.2016.63. Epub 2016 Apr 15.

43.

Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy.

Chalfin HJ, Liu JJ, Gandhi N, Feng Z, Johnson D, Netto GJ, Drake CG, Hahn NM, Schoenberg MP, Trock BJ, Scott AV, Frank SM, Bivalacqua TJ.

Ann Surg Oncol. 2016 Aug;23(8):2715-22. doi: 10.1245/s10434-016-5193-4. Epub 2016 Mar 24.

PMID:
27012987
44.

Nightly sildenafil use after radical prostatectomy has adverse effects on urinary convalescence: Results from a randomized trial of nightly vs on-demand dosing regimens.

Hyndman ME, Bivalacqua TJ, Mettee LZ, Su LM, Trock BJ, Pavlovich CP.

Can Urol Assoc J. 2015 Nov-Dec;9(11-12):414-9. doi: 10.5489/cuaj.3169. Epub 2015 Nov 9. Erratum in: Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E81.

45.

Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy.

Faraj SF, Bezerra SM, Yousefi K, Fedor H, Glavaris S, Han M, Partin AW, Humphreys E, Tosoian J, Johnson MH, Davicioni E, Trock BJ, Schaeffer EM, Ross AE, Netto GJ.

PLoS One. 2016 Jan 5;11(1):e0146189. doi: 10.1371/journal.pone.0146189. eCollection 2016.

46.

Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.

Tosoian JJ, Sundi D, Trock BJ, Landis P, Epstein JI, Schaeffer EM, Carter HB, Mamawala M.

Eur Urol. 2016 Apr;69(4):576-581. doi: 10.1016/j.eururo.2015.09.032. Epub 2015 Oct 9.

PMID:
26456680
47.

Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance.

Reese AC, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB.

Urology. 2015 Nov;86(5):991-5. doi: 10.1016/j.urology.2015.07.039. Epub 2015 Aug 31.

PMID:
26335496
48.

Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.

Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB.

J Clin Oncol. 2015 Oct 20;33(30):3379-85. doi: 10.1200/JCO.2015.62.5764. Epub 2015 Aug 31.

50.

Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.

Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humphreys EB, Faraj S, Bezerra SM, Han M, Partin AW, Trock BJ, Schaeffer EM.

Eur Urol. 2016 Jan;69(1):157-65. doi: 10.1016/j.eururo.2015.05.042. Epub 2015 Jun 6.

PMID:
26058959

Supplemental Content

Loading ...
Support Center